These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15609905)

  • 1. [New anti-arrhythmics--hope or disappointment?].
    Touboul P
    Arch Mal Coeur Vaiss; 2004 Nov; 97(11):1048-53. PubMed ID: 15609905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety of new anti-arrhythmic drugs].
    Touboul P
    Arch Mal Coeur Vaiss; 2005 Apr; 98(4):313-6. PubMed ID: 15881847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ion channels and arrhythmias].
    Borchard U; Hafner D
    Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dronedarone: a new antiarrhythmic agent.
    Oyetayo OO; Rogers CE; Hofmann PO
    Pharmacotherapy; 2010 Sep; 30(9):904-15. PubMed ID: 20795846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
    Wegener FT; Ehrlich JR; Hohnloser SH
    J Cardiovasc Electrophysiol; 2006 Sep; 17 Suppl 2():S17-20. PubMed ID: 16939434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm.
    Sideris S; Bonios M; Melexopoulou C; Exarchos P; Tsatiris K; Kogias J
    Cardiology; 2007; 107(4):399-401. PubMed ID: 17284902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
    Tisdale JE; Overholser BR; Sowinski KM; Wroblewski HA; Amankwa K; Borzak S; Kingery JR; Coram R; Zipes DP; Flockhart DA; Kovacs RJ
    Pharmacotherapy; 2008 Dec; 28(12):1461-70. PubMed ID: 19025427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation.
    Garcia D; Cheng-Lai A
    Cardiol Rev; 2009; 17(5):230-4. PubMed ID: 19690474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dronedarone.
    Patel C; Yan GX; Kowey PR
    Circulation; 2009 Aug; 120(7):636-44. PubMed ID: 19687370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia.
    Eidher U; Freihoff F; Kaltenbrunner W; Steinbach K
    Pacing Clin Electrophysiol; 2006 Apr; 29(4):358-62. PubMed ID: 16650262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ["Torsades de pointe" and reentry induced by anti-arrhythmia agents].
    Brochier M; Fauchier JP
    Arch Mal Coeur Vaiss; 1978 Apr; 71(4):477-88. PubMed ID: 78692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents.
    Dai DZ; Dai Y
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1001-8. PubMed ID: 18729007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What niche will newer class III antiarrhythmic drugs occupy?
    Singh BN; Sarma JS
    Curr Cardiol Rep; 2001 Jul; 3(4):314-23. PubMed ID: 11406090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety considerations in the pharmacological management of atrial fibrillation.
    Camm AJ
    Int J Cardiol; 2008 Jul; 127(3):299-306. PubMed ID: 18191470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R; Sami M
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.